TargetMol

Zoledronic Acid

Product Code:
 
TAR-T6739
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6739-25mg25mg£108.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6739-50mg50mg£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6739-100mg100mg£174.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6739-200mg200mg£226.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Zoledronate is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronate is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis.
CAS:
118072-93-8
Formula:
C5H10N2O7P2
Molecular Weight:
272.09
Pathway:
Autophagy; Cell Cycle/Checkpoint; Apoptosis
Purity:
0.9993
SMILES:
OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O
Target:
Apoptosis; Rho; Autophagy

References

Croucher PI, et al. J Bone Miner Res, 2003, 18(3), 482-492. Jagdev SP, et al. Br J Cancer, 2001, 84(8), 1126-1134. Jiang Z, Qin L, Tang Y, et al. Human induced-T-to-natural killer cells have potent anti-tumour activities. Biomarker Research. 2022, 10(1): 1-22. Viereck V, et al. Biochem Biophys Res Commun, 2002, 291(3), 680-686.